MX356281B - Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina. - Google Patents
Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina.Info
- Publication number
- MX356281B MX356281B MX2011004572A MX2011004572A MX356281B MX 356281 B MX356281 B MX 356281B MX 2011004572 A MX2011004572 A MX 2011004572A MX 2011004572 A MX2011004572 A MX 2011004572A MX 356281 B MX356281 B MX 356281B
- Authority
- MX
- Mexico
- Prior art keywords
- prolonged release
- derivate
- pyrrolidine
- oxo
- release formulations
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 230000002035 prolonged effect Effects 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 2
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 abstract 1
- 229960002161 brivaracetam Drugs 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 abstract 1
- 229950000852 seletracetam Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08105817 | 2008-11-18 | ||
| EP09100311 | 2009-06-02 | ||
| PCT/EP2009/065270 WO2010057869A1 (en) | 2008-11-18 | 2009-11-17 | Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2011004572A MX2011004572A (es) | 2011-06-17 |
| MX356281B true MX356281B (es) | 2018-05-22 |
Family
ID=41395028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011004572A MX356281B (es) | 2008-11-18 | 2009-11-17 | Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8460712B2 (enExample) |
| EP (1) | EP2358361B1 (enExample) |
| JP (2) | JP5954889B2 (enExample) |
| KR (2) | KR101788804B1 (enExample) |
| CN (2) | CN104083341A (enExample) |
| AU (1) | AU2009317279B2 (enExample) |
| BR (1) | BRPI0921301A2 (enExample) |
| CA (1) | CA2741038C (enExample) |
| DK (1) | DK2358361T3 (enExample) |
| EA (1) | EA019583B1 (enExample) |
| ES (1) | ES2602606T3 (enExample) |
| HK (1) | HK1198288A1 (enExample) |
| HU (1) | HUE030963T2 (enExample) |
| IL (1) | IL212271A (enExample) |
| MX (1) | MX356281B (enExample) |
| PL (1) | PL2358361T3 (enExample) |
| PT (1) | PT2358361T (enExample) |
| WO (1) | WO2010057869A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2358360T3 (en) * | 2008-11-18 | 2016-12-12 | Ucb Biopharma Sprl | EXTENDED release formulations comprising one 2-OXO-1 PYRROLIDIN DERIVATIVE |
| EP3397253A1 (en) | 2015-12-30 | 2018-11-07 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
| WO2017195144A1 (en) * | 2016-05-12 | 2017-11-16 | Jubilant Generics Limited | Pharmaceutical compositions comprising brivaracetam |
| CA3216586A1 (en) * | 2021-05-11 | 2022-11-17 | Caroline Roussel-Maupetit | Prolonged-release pharmaceutical composition for oral administration of sultiame |
| CN115721624A (zh) * | 2021-08-25 | 2023-03-03 | 北京海美源医药科技有限公司 | 一种布立西坦药物组合物及其制备方法和其应用 |
| TR2023017170A1 (tr) * | 2023-12-13 | 2025-06-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Bri̇varasetam i̇çeren bi̇r saşe formülasyonu |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| NZ556630A (en) * | 2005-01-27 | 2010-12-24 | Alembic Ltd | Extended release formulation of levetiracetam including a hydrophilic rate controlling polymer |
| US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| WO2006088864A1 (en) * | 2005-02-16 | 2006-08-24 | Elan Pharma International Limited | Controlled release compositions comprising levetiracetam |
| US8431156B2 (en) * | 2005-02-22 | 2013-04-30 | Sun Pharma Advanced Research Company Ltd. | Pharmaceutical composition |
| JP2008534530A (ja) * | 2005-03-29 | 2008-08-28 | エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング | 活性成分放出に関して調節作用を有する物質を有するペレットを含有している多粒子薬剤形 |
| FR2897267A1 (fr) * | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
| BRPI0712325A2 (pt) * | 2006-06-08 | 2012-01-10 | Ucb Pharma Sa | processo para a preparação de co-cristais de pirrolidinonas, co-cristal, composição farmacêutica, e, uso de um co-cristal |
| ES2953390T3 (es) | 2006-08-31 | 2023-11-10 | Adare Pharmaceuticals Inc | Sistemas de administración de fármacos que comprenden disoluciones sólidas de fármacos débilmente básicos |
| WO2008062446A2 (en) * | 2006-09-14 | 2008-05-29 | Alembic Limited | An extended release composition of levetiracetam, which exhibits no adverse food effect |
| US9555006B2 (en) * | 2007-09-21 | 2017-01-31 | Evonik Roehm Gmbh | PH-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
| BRPI0908421C1 (pt) | 2008-03-03 | 2021-05-25 | Ucb Biopharma Sprl | solução estável de um composto farmacêutico |
-
2009
- 2009-11-17 DK DK09752825.1T patent/DK2358361T3/en active
- 2009-11-17 EA EA201100753A patent/EA019583B1/ru unknown
- 2009-11-17 HU HUE09752825A patent/HUE030963T2/en unknown
- 2009-11-17 PL PL09752825T patent/PL2358361T3/pl unknown
- 2009-11-17 ES ES09752825.1T patent/ES2602606T3/es active Active
- 2009-11-17 US US13/128,950 patent/US8460712B2/en active Active
- 2009-11-17 PT PT97528251T patent/PT2358361T/pt unknown
- 2009-11-17 JP JP2011543762A patent/JP5954889B2/ja active Active
- 2009-11-17 BR BRPI0921301A patent/BRPI0921301A2/pt not_active IP Right Cessation
- 2009-11-17 WO PCT/EP2009/065270 patent/WO2010057869A1/en not_active Ceased
- 2009-11-17 CN CN201410370727.9A patent/CN104083341A/zh active Pending
- 2009-11-17 CA CA2741038A patent/CA2741038C/en active Active
- 2009-11-17 CN CN2009801455887A patent/CN102215828A/zh active Pending
- 2009-11-17 EP EP09752825.1A patent/EP2358361B1/en active Active
- 2009-11-17 KR KR1020177000418A patent/KR101788804B1/ko active Active
- 2009-11-17 KR KR1020117014019A patent/KR20110089184A/ko not_active Ceased
- 2009-11-17 AU AU2009317279A patent/AU2009317279B2/en active Active
- 2009-11-17 MX MX2011004572A patent/MX356281B/es active IP Right Grant
-
2011
- 2011-04-12 IL IL212271A patent/IL212271A/en active IP Right Grant
-
2014
- 2014-11-21 HK HK14111805.6A patent/HK1198288A1/xx unknown
-
2015
- 2015-03-31 JP JP2015071166A patent/JP2015143256A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN102215828A (zh) | 2011-10-12 |
| EA019583B1 (ru) | 2014-04-30 |
| IL212271A (en) | 2016-10-31 |
| EP2358361A1 (en) | 2011-08-24 |
| WO2010057869A1 (en) | 2010-05-27 |
| HUE030963T2 (en) | 2017-06-28 |
| IL212271A0 (en) | 2011-06-30 |
| MX2011004572A (es) | 2011-06-17 |
| BRPI0921301A2 (pt) | 2015-12-29 |
| ES2602606T3 (es) | 2017-02-21 |
| KR101788804B1 (ko) | 2017-10-20 |
| EP2358361B1 (en) | 2016-09-14 |
| US8460712B2 (en) | 2013-06-11 |
| EA201100753A1 (ru) | 2012-01-30 |
| AU2009317279A1 (en) | 2010-05-27 |
| CA2741038A1 (en) | 2010-05-27 |
| KR20170007528A (ko) | 2017-01-18 |
| JP2012509356A (ja) | 2012-04-19 |
| PT2358361T (pt) | 2016-11-18 |
| CN104083341A (zh) | 2014-10-08 |
| PL2358361T3 (pl) | 2017-02-28 |
| DK2358361T3 (en) | 2016-12-12 |
| JP5954889B2 (ja) | 2016-07-20 |
| US20110274762A1 (en) | 2011-11-10 |
| HK1198288A1 (en) | 2015-03-27 |
| KR20110089184A (ko) | 2011-08-04 |
| AU2009317279B2 (en) | 2013-10-24 |
| CA2741038C (en) | 2015-01-13 |
| JP2015143256A (ja) | 2015-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX339852B (es) | Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina. | |
| WO2008006528A3 (en) | Pharmaceutical compositions comprising levetiracetam | |
| WO2009117130A3 (en) | Extended release forumulation containing a wax | |
| WO2010021607A3 (en) | Pharmaceutical formulation | |
| WO2009100441A3 (en) | Depot formulations | |
| IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
| PL2280611T3 (pl) | Kompozycje składników aktywnych rozpuszczalnych w tłuszczach, zawierających gumę ghatti | |
| WO2011017502A3 (en) | Linaclotide-containing formulations for oral administration | |
| WO2012021715A3 (en) | Stable formulations of linaclotide | |
| EA201590805A1 (ru) | Композиция с немедленным и пролонгированным высвобождением | |
| MX356281B (es) | Formulaciones de liberacion prolongada que comprenden un derivado de 2-oxo-1-pirrolidina. | |
| JO2831B1 (en) | Quinclidine carbonate derivatives and pharmaceutical compounds | |
| EA201071218A1 (ru) | Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью | |
| TN2011000282A1 (en) | Alkaloid aminoester derivatives and medicinal composition thereof | |
| TN2012000147A1 (en) | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | |
| MY157673A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| UA103025C2 (ru) | Твердая композиция лекарственного средства замедленного высвобождения | |
| WO2012002730A3 (ko) | 봉독 추출물을 함유하는 피부 미백 및 보습용 조성물 | |
| WO2011002422A3 (en) | Solubility enhancing pharmaceutical formulation | |
| WO2013170086A3 (en) | Formulations for the delivery of active ingredients | |
| MX2010008365A (es) | Formulacion de liberacion sostenida que comprende octreotido y tres polimeros lineales de polilactido-co-glicolido. | |
| WO2011139252A3 (en) | Efervescent formulations comprising cefdinir | |
| MX2007013327A (es) | Formulaciones de liberacion prolongada. | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| MX2011011203A (es) | Sal de acido isetionico que contiene nitrogeno en formulaciones agricolas, estables, que pueden registrarse. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |